A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
Portfolio Pulse from Benzinga Insights
Tarsus Pharmaceuticals (NASDAQ:TARS) has been analyzed by 4 analysts, showing a shift towards a more cautious stance in the last 30 days with ratings ranging from bullish to indifferent. The average 12-month price target for TARS has been raised to $49.00, indicating a 19.51% increase from the previous target. The company, focusing on ophthalmic conditions treatment, has shown significant revenue growth but struggles with profitability and efficiency metrics.
February 29, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tarsus Pharmaceuticals has received mixed analyst ratings but an increased average price target of $49.00. The company's significant revenue growth contrasts with its profitability challenges.
The increase in the average price target suggests a positive outlook on Tarsus Pharmaceuticals' growth potential, particularly in revenue. However, the mixed analyst ratings and the company's challenges in profitability and efficiency metrics may temper short-term stock performance. The focus on developing treatments for ophthalmic conditions, including its lead candidate TP-03, indicates a strong product pipeline that could drive future growth.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100